Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
ImClone Systems LLC history
ImClone Systems LLC company history timeline
Founding ImClone in 1984
As the situation at Mount Sinai soured for Waksal, he took a leave of absence in 1984 to establish ImClone, an endeavor to which he would devote all his energy after exiting Mount Sinai.
1984: The company is incorporated.
The Wall Street Journal interviewed Alexandra Bona who worked for Waksal: "'One day in 1985, the Waksal lab imploded,' she recalls.
In 1986 ImClone opened its own laboratories, located in Manhattan's SoHo district on the site of a bankrupt shoe factory.
According to Business Week, "Over the next few years, Sam engineered several funding deals to keep ImClone alive until the company went through with its IPO in 1991.
Charles Berner of Yardley, Pa., has owned ImClone stock since its initial public offering in 1991. “If Sam didn’t do the thing that he did way back and it wasn’t tainted by the Martha Stewart thing,” Mr.
To move into clinical trials as soon as possible the Waksals bought a former New Jersey computer-chip factory and retrofitted it to produce the drug, which began to be tested on human patients in 1994, the same year that the biotech stocks suffered another crash.
That emphasis would shift in 1999 when Erbitux was used on a patient named Shannon Kellum, who had colon cancer that spread to her liver and abdomen.
The initial 125-patient study launched in 1999 was another gamble for the company, limited to patients who had already failed irinotecan treatment.
According to a 2002 New York Times profile, "Doctor Waksal has been sued several times for not paying his bills.
When the stock was at its nadir in 2002, Bristol-Myers could have picked up the rest of ImClone for a song.
Despite all the controversy surrounding the company, ImClone's fortunes, as well as the price of its stock, began to rebound in 2003, mostly on the strength of continuing efforts by Merck KgaA to gain approval for Erbitux in Europe.
Icahn took control of ImClone’s board of directors following a proxy fight in October 2006.
Rate ImClone Systems LLC's efforts to communicate its history to employees.
ImClone Systems LLC jobs
Do you work at ImClone Systems LLC?
Is ImClone Systems LLC's vision a big part of strategic planning?
ImClone Systems LLC competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Regeneron | 1988 | $14.2B | 9,123 | 317 |
| Seagen | 1997 | $2.0B | 900 | - |
| United Therapeutics | 1996 | $2.9B | 950 | 216 |
| Sanofi Genzyme | 1981 | $4.6B | 12,000 | - |
| Exelixis | 1994 | $2.2B | 484 | 160 |
| Amgen | 1980 | $33.4B | 22,000 | 679 |
| Merck | 1891 | $64.2B | 74,000 | 2,283 |
| Editas Medicine | 2013 | $32.3M | 133 | 2 |
| MannKind | 1991 | $10.0M | 233 | 47 |
| CIMA Labs | 1986 | $8.5M | 120 | 18 |
ImClone Systems LLC history FAQs
Zippia gives an in-depth look into the details of ImClone Systems LLC, including salaries, political affiliations, employee data, and more, in order to inform job seekers about ImClone Systems LLC. The employee data is based on information from people who have self-reported their past or current employments at ImClone Systems LLC. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by ImClone Systems LLC. The data presented on this page does not represent the view of ImClone Systems LLC and its employees or that of Zippia.
ImClone Systems LLC may also be known as or be related to ImClone Systems LLC and Imclone Systems.